Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 26Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Ipilimumab 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Antineoplastic Agents × Tumor-Agnostic × 1 year × Clear all
NCT06877533 2025-08-12

A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors

iTeos Therapeutics

Phase 1 Terminated
3 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡